NS-2359

NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.[2] The results did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[3] phase II having been completed in 2007.[4] A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]

NS-2359
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
PubChem CID
UNII
Chemical and physical data
FormulaC15H19Cl2NO
Molar mass300.22 g·mol−1
3D model (JSmol)
SMILES
  • Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3
  (verify)

See also

References
  1. "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". NeuroSearch.
  2. Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, et al. (May 2012). "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology. 26 (5): 653–62. doi:10.1177/0269881111424931. PMID 22048884. S2CID 9365152.
  3. Wilens TE, Klint T, Adler L, West S, Wesnes K, Graff O, Mikkelsen B (June 2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions. 4: 24. doi:10.1186/1744-9081-4-24. PMC 2442604. PMID 18554401.
  4. Clinical trial number NCT00467428 for "Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder" at ClinicalTrials.gov
  5. Clinical trial number NCT00032916 for "Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.